Citi raised the firm’s price target on Boston Scientific to $92 from $90 and keeps a Buy rating on the shares. The analyst calls Q2 “another wild ride” for the medical technology sector. The earnings prints brought “several eye-opening and frankly shocking deliveries, changes to guidance, and stock price reactions,” the analyst tells investors in a research note. Citi expects an “interesting” September broker season, and looks for updated management commentary on patient volumes, capital equipment, and China. It reiterated its top picks of Boston Scientific (BSX), GE HealthCare (GEHC), and Insulet (PODD), looking for acceleration moving through the remainder of 2024 and into 2025.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BSX:
- Jefferies healthcare analyst to hold an analyst/industry conference call
- Boston Scientific Appoints New Director and Expands Board
- Boston Scientific removed from ‘Analyst Current Favorites’ at Raymond James
- Boston Scientific price target raised to $91 from $85 at Raymond James
- Boston Scientific price target raised to $78 from $73 at Deutsche Bank